AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Repligen to Attend Three Investor Conferences in September
ByAinvest
Friday, Aug 22, 2025 7:32 am ET1min read
Repligen Corporation, a life sciences company, announced its participation in three investor conferences. Olivier Loeillot, CEO, will present at the Wells Fargo Healthcare Conference on September 4 and the Bank of America Global Healthcare Conference on September 25. Jason Garland, CFO, will participate in 1x1 meetings at the Deutsche Bank Healthcare Summit on September 10. Live webcasts of the presentations will be available on Repligen's Investor Relations website.
Repligen Corporation (NASDAQ: RGEN), a leading bioprocessing technology company in life sciences, has announced its participation in three significant investor conferences in September 2025. The company will be presenting at the Wells Fargo Healthcare Conference, the Deutsche Bank Healthcare Summit, and the Bank of America Global Healthcare Conference. Live webcasts of the presentations will be available on Repligen's Investor Relations website.At the Wells Fargo Healthcare Conference, scheduled from September 3 to 5 in Boston, CEO Olivier Loeillot will join an analyst discussion on September 4 at 8:00 a.m. ET. The Deutsche Bank Healthcare Summit, taking place on September 10 and 11 in New York City, will see CFO Jason Garland participate in 1x1 meetings on September 10. Finally, at the Bank of America Global Healthcare Conference, from September 23 to 25 in London, CEO Olivier Loeillot will participate in an analyst discussion on September 25 at 6:35 a.m. ET. Live webcasts of these events will be available on Repligen’s Investor Relations website.
Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems. These technologies aim to enhance the efficiency of manufacturing biological drugs, primarily for biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. The company's headquarters are located in Waltham, Massachusetts, with manufacturing sites across several countries, including the United States, Estonia, France, Germany, Ireland, the Netherlands, and Sweden.
For more information about Repligen Corporation, visit their website at [Repligen Corporation](https://www.repligen.com) and follow them on LinkedIn.
References:
[1] https://www.stocktitan.net/news/RGEN/repligen-corporation-to-present-at-upcoming-september-jzxm1p0l9340.html
[2] https://www.biospace.com/press-releases/restart-life-sciences-provides-corporate-update-on-strategy-and-growth-initiatives
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet